Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
February 29, 2024 06:00 ET
|
Medigene AG
Multiple members of management as expert speakers including Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene, Dr. Barbara Lösch, Head of Technology & Innovation and Dr. Kirsty...
Medigene to Present at Upcoming Conferences
February 19, 2024 08:00 ET
|
Medigene AG
Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
February 12, 2024 08:00 ET
|
Medigene AG
Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015MDG1015 is a first-in-class, third generation TCR-T...
Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, December 19, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway
November 21, 2023 12:05 ET
|
Medigene AG
Lead program MDG1015 on track for CTA/IND approval in 2H 2024Prioritization of pipeline to accelerate the advancement of Medigene’s maturing KRAS-libraryProjected cash runway extended to Q1 2025....
Medigene amends 2023 financial guidance
November 21, 2023 12:00 ET
|
Medigene AG
Planegg/Martinsried, November 21, 2023 The Executive Management Board of Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the...
Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11
November 04, 2023 12:00 ET
|
Medigene AG
Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene Reports Financial Results and Corporate Update for Q3 2023
October 26, 2023 02:30 ET
|
Medigene AG
Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for...
Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing
October 23, 2023 03:00 ET
|
Medigene AG
Planegg/Martinsried, October 23, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023
October 16, 2023 08:00 ET
|
Medigene AG
Planegg/Martinsried, October 16, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...